论文部分内容阅读
目的探讨老年与中青年非小细胞肺癌患者临床特征与治疗特点。方法对北京协和医院肿瘤内科2002年5月至2010年12月收治的晚期非小细胞肺癌老年组(≥70岁,101例)与中青年组(≤60岁,127例)的化疗强度、效果和毒副反应进行分析。主要研究指标是疾病控制率、客观有效率、到疾病进展时间,次要研究指标是内科合并症、化疗毒副反应。结果老年组合并症多于中青年组(87.1%vs.28.3%,P<0.05)。一线化疗中青年组比老年组疾病控制率(56.1%vs.58.2%)、客观有效率(13.4%vs.9.1%)有显著性差异,到疾病进展时间无显著差异(6.0个月vs.5.1个月)。血液学毒性老年组与中青年组相当(28.4%vs.21.1%,P>0.05),老年组心脑血管及肝肾并发症、系统性感染多于中青年患者(44.3%vs.10.9%,P<0.05)。结论年龄因素并不影响化疗疗效及增加血液学毒副反应,老年患者需要更加关注心脑血管及肝肾并发症、预防感染。
Objective To investigate the clinical characteristics and treatment characteristics of elderly and young patients with non-small cell lung cancer. Methods The intensity and effect of chemotherapy in elderly NSCLC patients (≥70 years, 101 cases) and middle-aged and young patients (≤60 years, 127 cases) admitted to Peking Union Medical College Hospital from May 2002 to December 2010 were analyzed retrospectively. And toxic side effects analysis. The main research indicators are disease control rate, objective and efficient, to disease progression time, secondary research indicators are medical comorbidities, chemotherapy side effects. Results Complications of elderly group were more than those of middle-aged group (87.1% vs.28.3%, P <0.05). The first-line chemotherapy in the elderly group than the elderly disease control rate (56.1% vs.58.2%), the objective efficiency (13.4% vs.9.1%) were significant differences in disease progression time was no significant difference (6.0 months vs.5.1 Month). Hematologic toxicities were comparable with those in middle-aged and young adults (28.4% vs.21.1%, P> 0.05). The elderly patients had more cardiovascular and liver-kidney complications and systemic infections than those in middle-aged and young patients (44.3% vs.10.9% P <0.05). Conclusion Age does not affect the curative effect of chemotherapy and increase hematological toxicities and side effects. Elderly patients need to pay more attention to cardiovascular, liver and kidney complications and prevent infection.